Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
CAMBRIDGE, Mass. - Vyome Holdings, Inc. (NASDAQ:HIND), currently trading at $13.65 with a market capitalization of $12.79 million, announced Monday that its Board of Directors will conduct a full review of strategic alternatives for Livechain Inc. (OTCID:LICH), in which Vyome holds a 70% controlling stake. According to InvestingPro data, the stock has shown resilience with a 3.08% gain year-to-date.
The clinical-stage healthcare holding company acquired its controlling interest in Livechain in 2021, initially intending to potentially establish a viable publicly held business on the OTC market. Now that Vyome trades on Nasdaq, the company sees an opportunity to explore different options for its Livechain holdings. The stock has been trading in a 52-week range of $11.61 to $14.89, demonstrating relative stability in a volatile market.
"We are keen to explore all ways to create value from this asset," said Krishna Gupta, Chairman of Vyome, in a press release statement. Gupta noted that many shareholders may be unaware of Vyome’s significant ownership position in Livechain.
The board plans to spend the next month evaluating various options, which could include launching a new business, forming a crypto treasury, merging with an existing business, or selling the stake entirely.
Vyome CEO Venkat Nelabhotla stated that with Vyome now trading on Nasdaq, "there is an opportunity to look at other creative options for LICH."
Vyome describes itself as a healthcare platform spanning the US-India innovation corridor, with a focus on leveraging clinical-stage assets to address immuno-inflammatory conditions.
The company has not yet formed an opinion on the best strategic path forward for its Livechain holdings. For investors seeking deeper insights into Vyome’s financial health and growth prospects, InvestingPro offers a comprehensive Pro Research Report, part of its coverage of over 1,400 US equities, providing detailed analysis and actionable intelligence for informed investment decisions.
In other recent news, Vyome Therapeutics, Inc. announced the completion of its merger with ReShape Lifesciences, leading to its listing on Nasdaq as Vyome Holdings, Inc. under the ticker symbol "HIND" starting August 15, 2025. This merger also prompted a 1-for-4 reverse stock split of ReShape’s common stock, effective the same day. Alongside these changes, Vyome will replace the entire ReShape leadership team with a new Board of Directors, which includes six members, four of whom are MIT alumni. In support of the merger, ReShape Lifesciences provided Vyome with a $200,000 loan to cover expenses related to the merger agreement, with repayment terms contingent on the merger’s completion.
Additionally, ReShape Lifesciences announced that it will receive a new patent on July 8, 2025, for its innovative intragastric balloon system. This patent covers a swallowable capsule designed for natural excretion after a three-month period. In other developments, ReShape Lifesciences has regained compliance with Nasdaq’s stockholders’ equity requirement, securing its continued listing on the Nasdaq Capital Market. These recent developments reflect significant transitions and strategic advancements for both Vyome and ReShape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.